Natural Killer Cells

[Intellia Therapeutics, Inc.] Intellia Therapeutics, Inc., a company focused on developing curative therapies leveraging CRISPR-based technologies, and ONK Therapeutics Ltd., a company dedicated to developing optimally engineered NK cell therapies to treat cancer, announced a licensing and collaboration agreement.

[Trends in Molecular Medicine] Scientists characterized NK cells in healthy individuals and immunocompromised patients in the course of an anti-SARS-CoV-2 BNT162b2 mRNA prospective, open-label clinical vaccine trial.

[Clinical Cancer Research] Researchers characterized changes in the soft tissue sarcoma tumor immune microenvironment induced by standard neoadjuvant therapy with the goal of informing neoadjuvant immunotherapy trial design.

[Haematologica] Researchers developed a CD38 CAR-NK cell therapy for acute myeloid leukemia, first by using an NK cell line which had low baseline CD38 expression and subsequently NK cells expanded from healthy donors.

[Scientific Reports] Using in silico and in vitro techniques, investigators demonstrated heterogeneous expression of CD97, a leukocyte adhesion marker, in human glioblastoma.

[Molecular Therapy-Oncolytics] The authors provide an overview of current and on-going chimeric antigen receptor (CAR) T cell clinical studies in pancreatic cancer and the major challenges and strategies to improve CAR T cell efficacy.